The potential US crackdown on WuXi AppTec and its affiliates is causing significant concern within the biopharmaceutical industry, highlighting the company's critical role as a partner to many biopharma companies. Experts warn that cutting ties with WuXi, especially when companies are on tight timelines and facing financial pressures, could lead to severe consequences, including exacerbating the drug shortage problem in the US. This situation, described as "TOO BIG TO FAIL?", has prompted discussions in biotech boardrooms about the need for backup plans or alternatives, with almost everyone looking for a plan B. The importance of WuXi and the potential impact of US policies on the biopharma sector have been extensively covered in recent reports, underscoring the industry's unpreparedness for such a shift. In a Feb. 21 regulatory filing, Lilly mentioned its dependence on 'China-based partners,' highlighting the widespread concern.
If you read one thing today make it @Jared_Whitlock's excellent story on the wide-ranging consequences for the drug industry from a potential geopolitical crackdown on WuXi: https://t.co/zFD0Lzfkrx
Must read from @Jared_Whitlock RE implications of WuXi crackdown. Many difficult BOD mtgs happening in biotech discussing whether+when to pull out of CROs/CDMOs in adversary countries👇 https://t.co/2huQkREF5I
One of the concerns mentioned in the story is that banning WuXI or (making it impossible for US biopharmas to work w/ them) has a high risk of exacerbating the drug shortage problem in the US. "In a Feb. 21 regulatory filing, Lilly said it’s dependent on 'China-based partners'… https://t.co/SwUqG9Zi3v
TOO BIG TO FAIL? WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down This is 100% a topic of discussion in every biotech BOD room and almost everyone is looking for a backup or plan B https://t.co/kr7Qz4XXPR https://t.co/ZTVGvllNEX
I reviewed securities filings and interviewed companies to show the impact of a proposed US crackdown on WuXi AppTec and its affiliates. https://t.co/wX6uri0koD
"You're on a tight timeline, you’ve got cash running out, and you’ve got to get into the clinic, and all of a sudden they can't manufacture your Phase I material... that’s going to be bad" What happens if the US forces biopharma to cut ties with WuXi: https://t.co/s65gEnqNlw
More great coverage of the consequences of the US-China tension in biopharma, from @Jared_Whitlock https://t.co/3RgjwBJwSG
New from @Jared_Whitlock: WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down https://t.co/K2igltaKJ9